Addex Therapeutics (NASDAQ:ADXN) Stock Price Down 5.5% – Here’s What Happened

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) shares fell 5.5% during trading on Monday . The stock traded as low as $7.30 and last traded at $7.4250. 6,258 shares traded hands during trading, a decline of 64% from the average session volume of 17,523 shares. The stock had previously closed at $7.86.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Addex Therapeutics Price Performance

The company has a market capitalization of $7.87 million, a price-to-earnings ratio of -1.26 and a beta of 1.37. The stock has a 50 day simple moving average of $9.08 and a two-hundred day simple moving average of $8.66.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings data on Monday, September 29th. The company reported ($2.91) EPS for the quarter. Addex Therapeutics had a net margin of 3,584.49% and a negative return on equity of 68.40%.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.